pharmaphorum
LightNews LightNews
banner
pharmaphorum.bsky.social
pharmaphorum
@pharmaphorum.bsky.social
140 followers 480 following 1.3K posts
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
Posts Replies Media Videos
pharmaphorum.bsky.social
In today’s news: lnkd.in/epS2jdQn
#pharma #pharmanews #newsoftheday
February 6, 2026 at 4:56 PM
pharmaphorum.bsky.social
Three years after its first launch in the US, there are signs that #Biogen and #Eisai's #Alzheimer's #Leqembi therapy is gathering sales momentum.

pharmaphorum.com/news/leqembi...
February 6, 2026 at 4:19 PM
pharmaphorum.bsky.social
#Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic #stroke by 26%, according to the OCEANIC-STROKE trial.

pharmaphorum.com/news/bayer-r...
February 6, 2026 at 1:58 PM
pharmaphorum.bsky.social
The #Trump administration's long-promised direct-to-consumer sales channel for medicines, #TrumpRx, has finally gone live.

pharmaphorum.com/news/white-h...
White House's TrumpRx platform has arrived
The Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, has finally gone live
pharmaphorum.com
February 6, 2026 at 1:37 PM
pharmaphorum.bsky.social
Competition has already arrived for Novo Nordisk's #Wegovy pill, as #telehealth company Hims & Hers launches a compounded version. #GLP1 #ObesityDrugs #WeightLossMedication #HimsAndHers #HealthNews #pharma
pharmaphorum.com/news/hims-he...
Hims & Hers copies Novo Nordisk's new Wegovy pill
Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version
pharmaphorum.com
February 6, 2026 at 10:24 AM
pharmaphorum.bsky.social
#GenerateBiomedicines has filed for an #IPO on the #Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly #asthma drug. #lifesciences #biotechnews #respiratoryhealth pharmaphorum.com/news/flagshi...
February 5, 2026 at 2:29 PM
pharmaphorum.bsky.social
#Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated #vasculitis from the US market. #ANCAAssociatedVasculitis
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...
February 5, 2026 at 2:24 PM
pharmaphorum.bsky.social
#Grail has teamed up with #telehealth company #HimsAndHers to boost access to its recently filed #Galleri blood test for multi-cancer screening. #MultiCancerEarlyDetection #CancerScreening #oncology #DigitalHealth #pharmanews pharmaphorum.com/news/grail-m...
Grail multi-cancer test taps into Hims & Hers network
Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening
pharmaphorum.com
February 5, 2026 at 12:17 PM
pharmaphorum.bsky.social
A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can now be used routinely by the #NHS to monitor patients with #heartfailure. #pharmanews #lifesciences pharmaphorum.com/news/abbotts...
Abbott's wireless heart failure sensor cleared for NHS use
A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can now be used routinely by the NHS to monitor patients with heart failure
pharmaphorum.com
February 5, 2026 at 12:05 PM
pharmaphorum.bsky.social
Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing. #pharmanews #lifescience
pharmaphorum.com/news/eikon-v...
Eikon, Veradermics close IPOs, as Salspera joins queue
Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing
pharmaphorum.com
February 5, 2026 at 10:03 AM
pharmaphorum.bsky.social
In today’s news: pharmaphorum.com/news #pharmanews
February 4, 2026 at 4:56 PM
pharmaphorum.bsky.social
#EliLilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on #NovoNordisk. pharmaphorum.com/news/lilly-s...
Lilly says 2026 looks good, as sales rocket in Q4
Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk
pharmaphorum.com
February 4, 2026 at 2:45 PM
pharmaphorum.bsky.social
Luke Miels' first financial results since taking over as chief executive of #GSK revealed a jump in sales and profits. #pharmanews #lifesciences pharmaphorum.com/news/gsk-del...
GSK delivers in new CEO Miels' first financial update
Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits
pharmaphorum.com
February 4, 2026 at 1:47 PM
pharmaphorum.bsky.social
Squeezed by "unprecedented" #pricing pressures, Novo Nordisk has forecast a decline in revenues this year. #pharmanews #lifesciences
pharmaphorum.com/news/novo-no...
Novo Nordisk slumps on tougher 2026 financial outlook
Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.
pharmaphorum.com
February 4, 2026 at 1:45 PM
pharmaphorum.bsky.social
#Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky. #pharmanews #lifesciences pharmaphorum.com/news/patent-...
Patent losses hit Novartis hard, but CEO has a plan
Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky
pharmaphorum.com
February 4, 2026 at 11:13 AM
pharmaphorum.bsky.social
The UK confirms that the cost of the #drugpricing deal with the US, initially around £1bn over three years, will be borne by the health department. #pharmanews #healthnews #lifesciences #healthpolicy pharmaphorum.com/news/fears-u...
Fears US drug pricing deal will weigh heavy on the NHS
The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department
pharmaphorum.com
February 4, 2026 at 10:39 AM
pharmaphorum.bsky.social
In today's headlines: pharmaphorum.com/news
February 3, 2026 at 5:06 PM
pharmaphorum.bsky.social
#FDA has delivered a setback to #AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

pharmaphorum.com/news/fda-kno...
FDA knocks back AstraZeneca's self-injected lupus drug
FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year
pharmaphorum.com
February 3, 2026 at 2:24 PM
pharmaphorum.bsky.social
Families of young people with cancer in England will have the costs of travelling to medical appointments covered under a new funding scheme.

pharmaphorum.com/news/uk-will...
UK will cover transport costs for children with cancer
Families of young people with cancer in England will have the costs of travelling to medical appointments covered under a new funding scheme
pharmaphorum.com
February 3, 2026 at 11:48 AM
pharmaphorum.bsky.social
#NovoNordisk is considering filing #CagriSema for diabetes, in addition to #obesity, after it outperformed #Ozempic in a head-to-head study.

pharmaphorum.com/news/novo-no...
Novo Nordisk's CagriSema tops Ozempic in diabetes trial
Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study
pharmaphorum.com
February 3, 2026 at 11:40 AM
pharmaphorum.bsky.social
Wave Life Sciences has lost #GSK as the partner for its alpha-1 antitrypsin deficiency drug, but their other partnered RNA-editing programmes remain active.

pharmaphorum.com/news/gsk-kic...
GSK kicks out of Wave's AATD programme
Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active
pharmaphorum.com
February 3, 2026 at 10:44 AM
pharmaphorum.bsky.social
Sanofi been found to be in breach of the UK pharma industry's code of practice over an article in which it compared its #RSV jab to a #Pfizer rival.

pharmaphorum.com/news/uk-body...
UK body raps Sanofi for disparaging Pfizer's RSV jab
Sanofi been found to be in breach of the UK pharma industry's code of practice over an article in which it compared its RSV jab to a Pfizer rival
pharmaphorum.com
February 3, 2026 at 10:32 AM
pharmaphorum.bsky.social
The #FDA has turned down #Pharming's attempt to broaden the label of Joenja for rare #immunodeficiency disorder APDS, so it can be used in younger patients.

pharmaphorum.com/news/fda-kno...
FDA knocks back Pharming's bid for wider Joenja use
The FDA has turned down Pharming's bid to broaden the label of Joenja for rare immunodeficiency disorder APDS so it can be used in younger patients
pharmaphorum.com
February 2, 2026 at 2:22 PM
pharmaphorum.bsky.social
#Sanofi has reported positive phase 3 results with venglustat in Gauder disease, but the drug missed the mark in a Fabry disease trial.

pharmaphorum.com/news/mixed-d...
Mixed data mars Sanofi's venglustat programme
Sanofi has reported positive phase 3 results with venglustat in Gauder disease, but the drug missed the mark in a Fabry disease trial
pharmaphorum.com
February 2, 2026 at 1:38 PM
pharmaphorum.bsky.social
The #FDA has started accepting requests to participate in its PreCheck pilot programme, promising rapid reviews of new manufacturing facilities.

pharmaphorum.com/news/fda-lau...
FDA launches pilot programme to boost US manufacturing
The FDA has started accepting requests to participate in its PreCheck pilot programme, promising rapid reviews of new manufacturing facilities
pharmaphorum.com
February 2, 2026 at 11:41 AM